BCL2 and neutropenia: For instance, ABT‐263 (navitoclax), a BCL‐2 family inhibitor, is not only senolytic to senescent cells, but also cytotoxic against platelets and neutrophils, often resulting in thrombocytopenia and neutropenia (Leverson et al., 2015).